Carregando...
Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma
Clinical trials have demonstrated that rituximab improves overall survival in non-Hodgkin lymphoma (NHL), except in mantle cell lymphoma (MCL). We used Surveillance Epidemiology and End Results (SEER)–Medicare data to compare survival in older MCL patients who began chemotherapy with or without ritu...
Na minha lista:
| Principais autores: | , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society of Hematology
2011
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3208292/ https://ncbi.nlm.nih.gov/pubmed/21873544 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-04-348367 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|